H&T Presspart

What they make

1 input H&T Presspart supplies

Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.

Where they make it

1 facility

Intelligence

What's known

Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.

• Concentration2023

  H&T Presspart (Blackburn, Lancashire UK; subsidiary of H&T Group — the German family company Heinrich & Tischinger AG, founded 1842) claims that its pharmaceutical aluminum canisters are incorporated into approximately 85% of all pressurized metered-dose inhalers produced globally. This figure — if accurate — represents one of the most extreme single-company concentration ratios for any pharmaceutical component: one factory in one former cotton mill town in Lancashire, England makes the container for the respiratory medication of 260 million asthma and COPD patients worldwide. The internal coating of the canister (epoxy-phenol or fluoropolymer) is registered as part of each drug product's approved specifications — changing the canister supplier requires regulatory validation batches, dissolution testing, and typically a Prior Approval Supplement to FDA requiring 12+ months to approve. A fire, flood, strike, or regulatory shutdown at H&T Presspart's Blackburn facility would create a global shortage of pMDI inhalers with no practical near-term alternative. GSK, AstraZeneca, Boehringer Ingelheim, and every other major respiratory pharmaceutical company depend on a single converted cotton mill site in the former industrial heartland of Northern England.

  H&T Presspart Manufacturing Ltd. ↗

• Did you know2023

  H&T Presspart's pMDI canister propellant transition is being driven by the same international climate policy — the Kigali Amendment to the Montreal Protocol — that is simultaneously forcing the global HVAC industry to abandon R-410A and the automotive industry to transition from R-134a. Presspart's current MDI canisters use HFA 134a (GWP 1430) or HFA 227ea (GWP 3220) as the propellant that delivers asthma medication to the lung. The European Medicines Agency and EU F-gas regulations target phasing these propellants out of MDIs by 2025-2030 in favor of HFA 152a (GWP 150). HFA 152a is a different chemistry: mildly flammable (A2L class) requiring new canister coating, new actuator materials, and entirely new pharmaceutical stability data. Presspart's IPTC Blackburn facility is developing HFA 152a-compatible canister solutions. If Presspart's low-GWP canister fails regulatory qualification in time, it creates a direct conflict between climate policy (phase out high-GWP MDI propellants) and healthcare policy (maintain availability of life-saving asthma inhalers). The climate regulations affecting air conditioners and car ACs are creating a parallel crisis for respiratory medicine delivery — the same Kigali Amendment constrains both.

  H&T Presspart Manufacturing Ltd ↗

• Origin2023

  H&T Presspart holds approximately 85% of global pMDI aluminum canister supply — a near-monopoly on a pharmaceutical device component inside virtually every pressurized metered-dose inhaler globally. The MDI canister market is constrained by extreme qualification requirements: each new drug-canister-coating combination must be separately approved by the FDA and other regulators as a pharmaceutical combination product. This means Presspart's existing coatings and manufacturing processes are locked in by regulatory approval, and any competitor would need years of compatibility testing and regulatory submissions to enter the market. The company is a subsidiary of German tube manufacturer H&T Group, headquartered in Blackburn, Lancashire — an industrial town better known for textiles than pharmaceuticals. The regulatory moat around MDI canister manufacturing means that 300 million asthma and COPD patients globally depend for their rescue inhaler functionality on the manufacturing quality of a single Lancashire tube company.

  H&T Presspart Manufacturing Ltd ↗